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Abstract
Background: Parkinson’s’ disease (PD) and Multiple System Atrophy (MSA) are progressive brain disorders
characterized by intracellular accumulations of α-synuclein and nerve cell loss in specific brain areas. This loss
causes problems with movement, balance and/or autonomic functions. Naturally occurring autoantibodies (NAbs)
play potentially an important role in clearing or/and blocking circulating pathological proteins. Little is known
about the functional properties of anti-α-synuclein NAbs in PD and MSA, and there have been opposing reports
regarding their plasma concentrations in these disorders.
Methods: We have investigated the apparent affinity of anti-α-synuclein NAbs in plasma samples from 46 PD patients,
18 MSA patients and 41 controls using competitive enzyme-linked immunosorbent assay (ELISA) and Meso Scale
Discovery (MSD) set-ups.
Results: We found that the occurrence of high affinity anti-α-synuclein NAbs in plasma from PD patients is reduced
compared to healthy controls, and nearly absent in plasma from MSA patients. Also, levels of α-synuclein/NAbs
immunocomplexes is substantially reduced in plasma from both patient groups. Further, cross binding of anti-α-
synuclein NAbs with β- and γ-synuclein monomers suggest, the high affinity anti-α-synuclein plasma component,
seen in healthy individuals, is directed mainly against C-terminal epitopes. Furthermore, we also observed
reduced occurrence of high affinity anti-phosphorylated-α-synuclein NAbs in plasma from PD and MSA patients.
Conclusions: One interpretation implies that these patients may have impaired ability to clear and/or block the
effects of pathological α-synuclein due to insufficient/absent concentration of NAbs and as such provides a
rationale for testing immune-based therapeutic strategies directed against pathological α-synuclein. Following
this interpretation, we can hypothesize that high affinity autoantibodies efficiently bind and clear potentially
pathological species of α-synuclein in healthy brain, and that this mechanism is impaired or absent in PD and
MSA patients.
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Background
Abnormal intracellular aggregation of α-synuclein is a
pathological hallmark of Parkinson’s disease (PD),
where α-synuclein is a major constituent of neuronal
Lewy bodies, and Multiple System Atrophy (MSA),
where α-synuclein aggregates are found mainly in
oligodendroglia [1–3]. Both PD and MSA are associated
with the degeneration of nerve cells in specific areas of
the brain [4–6]. PD is the second most common neuro-
degenerative disorder among the elderly; only symp-
tomatic therapeutic interventions based on dopamine
replacement are available for the treatment of PD
patients [7]. Whereas, MSA is relatively rare, it pro-
gresses more rapidly than does PD and treatment is less
effective on motor symptoms, leading to death in less than
ten years after diagnosis [8, 9]. Although α-synuclein is
frequently assumed to be etiologically involved in these
conditions, the mechanisms driving α-synuclein aggrega-
tion and their relationship to disease progression and
neuronal degeneration are poorly understood [10].
A growing body of evidence from clinical studies and
preclinical animal models emphasize a role of the immune
system in the pathophysiology of PD [11, 12]. Naturally
occurring autoantibodies (NAbs) make up two-thirds of
the human antibody pool, and may be involved in diverse
aspects of immunological reactions including regulatory
and protective functions [13–15]. NAbs are now under-
stood to have access to the central nervous system,
where they are implicated in maintaining homeostasis
by removing cell debris and in preventing inflammation
by binding and neutralizing cytokines [16, 17]. A neu-
roprotective action of anti-α-synuclein antibodies has
been demonstrated in several animal models of PD. For
example, transgenic mice that produced high affinity anti-
bodies following immunization with human α-synuclein
displayed reduced intraneuronal accumulation of aggre-
gated human α-synuclein, and decreased degeneration of
dopamine neurons, apparently through promoting deg-
radation and clearance of aggregated human α-synuclein
via lysosomal pathways [18]. Also, antibodies specific for
misfolded α-synuclein, have been found to block uptake
and propagation of α-synuclein pathology in cell cul-
ture and in a mouse model [19]. Another study showed
that active immunization using α-synuclein peptides re-
duced the accumulation of α-synuclein oligomers (but
not monomers) and ameliorated the behavioral and
neurodegenerative pathology in two different transgenic
models of synucleinopathies [20, 21]. Furthermore, pas-
sive immunization studies using high affinity α-synuclein
antibodies have been successful in ameliorating α-synuclein
pathology and/or behavior in animal models [as reviewed
by Bergstrom et al. [22]].
The titre of anti-α-synuclein NAbs in serum or plasma
from PD patients has been the focus of previous
investigations. Whereas some studies showed non-
significant differences between PD patients and controls
groups [23–25], others have shown increased [26–28] or
decreased [29] α-synuclein NAbs levels in PD patients. To
our knowledge none of these reports investigated the
functional characteristics of anti-α-synuclein NAbs from
PD patients, nor have there been any reports on anti-α-
synuclein NAbs in MSA.
In general, the biological activity of an antiserum is
influenced not only by its concentration of specific anti-
bodies but also by its functional characteristics such as
affinity and/or avidity. Thus, the analysis of NAbs in
plasma antibody titer as well as affinity/avidity of the
antibodies is required. Yanamandra et al. has reported
that the immunoreactivity to α-synuclein is decreased in
late PD, which manifests in fewer patients exhibiting
marked immune responses towards α-synuclein [28].
We now report that the frequency of a high apparent
affinity phenotype of anti-α-synuclein NAbs in plasma of
PD patients is significantly reduced compared to healthy
individuals, whereas these antibodies are nearly undetect-
able in plasma of MSA patients. In contrast, all tested
individuals had abundance of anti-α-synuclein NAbs of
low apparent affinity reflecting unspecific binding
(affinity range > 1000 nM) or low affine polyreactivity
(100-1000 nM). We hypothesize that high affinity auto-
antibodies of the IgG sub-type efficiently bind and clear
potentially pathological species of α-synuclein in healthy
brain, and that this mechanism is impaired or absent in
PD and MSA patients.
Methods
Patients and healthy control individuals
All PD and MSA patients were followed by a movement
disorder specialist at the Movement Disorders Clinic,
Department of Neurology, Bispebjerg-Frederiksberg
Hospital, Copenhagen. The clinical diagnosis for PD was
defined according to UK Parkinson’s Disease Society
Brain Bank clinical diagnostic criteria [30]. The clinical
diagnosis of MSA was performed according to the
accepted clinical diagnostic criteria [31] and with initial
inclusion of cases with both possible and probable diag-
noses (either the parkinsonian or the cerebellar subtype).
Patients were included consecutively and a clinical
follow-up was performed for all patients. At follow-up
only those patients fulfilling the diagnostic criteria for a
probable or definite MSA (n = 18) or definite PD
(n = 46) diagnosis were accepted and included in the
study. All PD and MSA patients received levodopa treat-
ment. Healthy control volunteers (n = 41) were recruited
through general announcements or advertisements at
the hospital and were free of conditions that might affect
the central nervous system.
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Moreover, the following inclusion criteria were
applied: Male or female aged 18 years or older at screen-
ing, able to cooperate with consent procedures, able to
participate in study activities including all required clin-
ical assessments and biological donations. The exclu-
sion criteria comprised the following: Unable to
participate in consent procedures, current treatment
with anti-coagulants, unable to participate in biological
specimen collection due to a medical condition or medi-
cation status, parkinsonism of different nature than idio-
pathic, such as other forms of atypical or vascular
parkinsonism and severe dementia.
The Ethics Committee for the Copenhagen Regional
Area gave approval for this protocol (H-1-2011-093),
and all participants gave written informed consent.
For summarized patient and control demographic
characteristics see Table 1.
Plasma samples
Venous blood was drawn at the respective clinics and proc-
essed on the same day at Bispebjerg Movement Disorders
Biobank. All plasma samples were collected at inclusion.
Samples were collected in EDTA coated polypropylene
tubes, and were spun at 2000×g for 10 min at 4 °C; the
supernatant plasma was then aliquoted and stored in
400 μL polypropylene (PP) tubes at −80 °C until the day of
analysis, when they were thawed on ice for 30 min.
Measurement of Anti-α-Synuclein Antibodies by
Competitive ELISA
Levels and avidity of anti-α-synuclein NAbs were mea-
sured by competitive enzyme-linked immunosorbent assay
(ELISA). 96-well polystyrene microtiter plates (Nunc Max-
iSorp® flat-bottom 96 well plate) were coated with either
10 μg/mL or 5 μg/mL recombinant α-synuclein monomer
(rPeptide, #S-10001-2) in ice-cold 0.1 M carbonate buffer
(pH 8.5) overnight (>12 h) at 4 °C. The plates were emp-
tied and blocked for 2 h at room temperature (RT) with
3% bovine serum albumin (BSA) and 0.1% NP-40 in
phosphate-buffered saline (PBS, pH 7.4100 μL per well)
and washed 5 times with PBS + 0.05% Tween-20. Next,
50 μL portions of plasma (diluted 1:100, 1:200, and 1:400
in PBS + 0.1%BSA) were transferred to the coated plates
and incubated for 1 h at RT. For the competition reaction,
plasma samples were incubated before transfer onto plates
for 1 h with α-synuclein monomer at a range of concentra-
tions: (1000, 250, 62.5, 15.5, 3.9, 0.97 and 0.24 nM for
competition curve with plasma pools, and 1000, 50 and
2 nM for individual samples (the range of α-synuclein
monomer concentrations was decided after completing
preliminary experiments). After five washes with
PBS + 0.05% Tween 20, 50 μL of peroxidase-labeled
polyclonal goat anti-human IgG (Fc fragment specific;
Abcam #ab98567: 1:20,000 dilution) was added to each
well and incubated at RT for 2 h. After five more washes,
tetramethylbenzidine (TMB) Liquid Peroxidase Substrate
(50 μL; Sigma-Aldrich #T8665) was added, followed by
incubation in the dark at RT for 30 min. The reaction was
then stopped with 50 μL of 0.5 N H2SO4, and the absorb-
ance at 450 nm was measured on a Fisher Scientific™
Multiskan™ FC Microplate Reader.
Measurement of α-Synuclein Concentration by MSD Assay
System
The α-synuclein concentration in plasma samples was
measured with commercially available Human α-Synuclein
Kit from MSD (Meso Scale Discovery®; MULTI-ARRAY
Assay Systems, #K151TGD). The assay was performed as
per the manufacturer’s instructions, with 1:50 dilution of
plasma in Diluent-35, as provided by the manufacturer.
For measurement of α-synuclein–anti-α-synuclein anti-
body complexes, samples were incubated with Sulfo-TAG
Table 1 Demographic characteristics of control subjects, Parkinson’s Disease and Multiple System Atrophy patients
MSA patients PD patients Normal controls
N = 18 N = 46 N = 41
Age[years] (mean) 47–76 (62.5) 46–78 (62.4) 21–85 (43.9)
[SD] [9.2] [6.7] [14.2]
P < 0.001
Gender
Female/Male
12/6 17/27 43/7
Chi-squared test:
p < 0.0001
Age at onset [years] (mean) 42–75 (56.71) 37–74 (53.95)
[SD] [9.17] [9.05]
Disease duration [years] (mean) 1–10 (4.8) 1–22 (7.9) -
[SD] [2.6] [5.0]
Severity of the disease Hoehn
and Yahr Staging (median)
2.0–5.0 (3.0) 1.5–2.5 (2.0)
P < 0.0001
-
Demographic characteristics of control subjects, Parkinson’s Disease and Multiple System Atrophy patients
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anti-human IgG (MSD, #R32AJ-1). α-Synuclein/NAbs
complexes were quantified with reference to an α-synu-
clein standard curve. The plates were read using an MSD
Sector Imager S600 instrument, and the data analyzed
using Discover Workbench 4.0 software.
Measurement of Anti-α-Synuclein Antibodies by MSD
Assay System
To validate our ELISA results we have optimized an MSD
electrochemiluminescence assays to measure anti-α-
synuclein NAbs in plasma samples. MSD assays present
several advantages over traditional ELISAs, including
increased sensitivity and low background [32]. 96-well
microtiter plates (Standard MSD bind plate #L15XA-1)
were coated with either 5 ng/mL or 0.5 ng/mL of recom-
binant α-synuclein monomer (rPeptide, #S-10001-2) in
ice-cold 0.1 M carbonate buffer (pH 8.5) overnight (>12 h)
at 4 °C. The plates were washed 3 times with washing buf-
fer (PBS + 0.05% Tween 20) and blocked for 1 h at RT
with 3% BSA fraction V and 0.1% NP-40 in PBS, pH 7.4,
150 μL per well on a shaker set at 800 rpm. The plates
were washed 3 times with PBS + 0.05% Tween-20. The
25 μL portions of plasma (diluted 1:500 in PBS + 0.1%BSA
fraction V) were transferred to the coated plates and incu-
bated for 1 h at RT on the shaker. Before transfer
onto plates, plasma pools were incubated for 1 h with
α-synuclein monomer at a range of concentrations
8000, 2000, 500, 125, 31.2, 7.8, 1.95, 0.48, 0.122, 0.03
and 0.007 nM). The range of α-synuclein monomer and
plasma concentrations were decided after preliminary
experiments. Wells were then washed 3 times with
PBS + 0.05% Tween 20, and 25 μL of MSD Sulfo Tag Goat
anti-human IgG antibody (MSD #R32AJ-1; 1:500 dilution
in PBS + 0.1% BSA fraction V) was added to each well,
with incubation at RT for 1 h on the shaker. After three
more washes, MSD Read Buffer at 1:2 concentration di-
luted in MilliQ water was added to the wells. Immediately
afterwards, the plates were read using an MSD Sector
Imager S600 instrument.
Measurement of Anti-β/γ-Synuclein Antibodies by Com-
petitive ELISA
Levels and avidity of anti-β/γ-synuclein NAbs were mea-
sured by competitive enzyme-linked immunosorbent
assay (ELISA). 96-well polystyrene microtiter plates (Nunc
MaxiSorp® flat-bottom 96 well plate) were coated with
either 10 μg/mL recombinant β-synuclein monomer
(rPeptide,GA,USA, #S-1003-2) or 10 μg/mL recombinant
γ-synuclein monomer (rPeptide,GA,USA, #S-1007-1) in
ice-cold 0.1 M carbonate buffer (pH 8.5) overnight (>12 h)
at 4 °C. The plates were emptied and blocked for 2 h at
room temperature (RT) with 3% bovine serum albumin
(BSA) and 0.1%NP-40 in phosphate-buffered saline (PBS,
pH 7.4, 100 μL per well) and washed 5 times with
PBS + 0.05% Tween-20. Fifty μL portions of plasma
diluted 1:400 in PBS + 0.1%BSA were transferred to the
coated plates and incubated for 1 h at RT. For the compe-
tition reaction, before transfer onto plates, samples were
incubated for 1 h with either β-synuclein or γ-synuclein
monomer at a 2-fold dilution range of concentrations:
1000-2 nM for competition curve with plasma pools, and
1000, 100 and 10 nM for individual samples (the range
was decided after completing preliminary experiments).
After five washes with PBS + 0.05% Tween-20, 50 μL of
peroxidase-labeled polyclonal goat anti-human IgG
(Abcam, UK: 1:20,000 dilution) was added to each well
and incubated at RT for 2 h. After five more washes,
tetramethylbenzidine (TMB) Substrate (50 μL; Sigma-
Aldrich,MO,USA) was added. After 30 min the reaction
was then stopped with 50 μL of 0.5 N H2SO4, and the
absorbance at 450 nm was measured on a Fisher Scientific™
Multiskan™ FC Microplate Reader,MA,USA.
In vitro phosphorylation of human α-synuclein
Alpha-synuclein (Abcam #ab51189) was phosphorylated
using PLK 2 (Invitrogen Cat# PV4204) at a concentra-
tion of 1.44 mg/ml (100 μM). The phosphorylation reac-
tions were carried out in the presence of 1.09 mM ATP,
1× reaction solution (2 mM HEPES, 10 mM MgCl2,
2 mM DDT, pH 7.4) and 1 μg of PLK/144 μg/ml of
α-syn at 30 °C for 24 h. The reaction was quenched with
25 mM EDTA. After quenching the sample was desalted
on a G25 column (HiTrap Desalting, GE healthcare
#G-25 17–1408-01) into DPBS (Invitrogen #14190–094).
The sample was analyzed by LC-MS. Briefly; the sam-
ple was separated on a C4 2.1 × 50 mm BEH300 column
run in FA/ACN and introduced to a XEVO QTOF Mass
spectrometer (Waters). The multicharged signal obtained
from the ion trace was deconvoluted and the mass iden-
tified to be a mixture of a non-phosphorylated 14,459 Da
α-synuclein (minor component) and the major 14,539 Da
phosphorylated species corresponding to a + 80 Da change
caused by phosphorylation on serine 129.
Measurement of Anti-Phosporylated-α-Synuclein
Antibodies by Competitive MSD Assay System
We have optimized an MSD electrochemiluminescence
assays to measure binding properties of anti-P-α-synuclein
NAbs in plasma samples. 96-well microtiter plates
(Standard MSD bind plate #L15XA-1) were coated
with either 5 ng/mL recombinant α-synuclein mono-
mer (rPeptide, #S-10001-2) or 5 ng/mL P-α-synuclein
in ice-cold 0.1 M carbonate buffer (pH 8.5) overnight
(>12 h) at 4 °C. The plates were washed 3 times with
washing buffer (PBS + 0.05% Tween 20) and blocked for
1 h at RT with 3% BSA fraction V and 0.1% NP-40 in PBS,
pH 7.4, 150 μL per well on a shaker set at 800 rpm. The
plates were washed 3 times with PBS + 0.05% Tween-20.
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The 25 μL portions of plasma (diluted 1:400 in
PBS + 0.1%BSA fraction V) were transferred to the coated
plates and incubated for 1 h at RT on the shaker. Before
transfer onto plates, plasma samples were incubated for
1 h with α-synuclein monomer at 1 μM and a range of P-
α-synuclein concentrations 10, 1, and 0.1 nM. For compe-
tition curve, plasma pools (diluted 1:400 in PBS + 0.1%BSA
fraction V) were incubated for 1 h with P-α-synuclein at a
3-fold dilution range of concentrations 100 nM-0.3pM.
The range of P-α-synuclein and plasma concentrations
were decided after preliminary experiments.
Wells were then washed 3 times with PBS + 0.05%
Tween 20, and 25 μL of MSD Sulfo Tag Goat anti-
human IgG antibody (MSD #R32AJ-1; 1:500 dilution in
PBS + 0.1% BSA fraction V) was added to each well,
with incubation at RT for 1 h on the shaker. After three
more washes, MSD Read Buffer at 1:2 concentration di-
luted in MilliQ water was added to the wells. Immedi-
ately afterwards, the plates were read using an MSD
Sector Imager S600 instrument.
Cross-binding inhibition assays
To obtain the two site inhibition curves, ten plasma
samples from each group were pooled and incubated in
1:400 dilution with increasing concentration of α-, β-,
and γ-synuclein monomers at a 2-fold dilution range of
concentrations 1000-2 nM, in combinations: α- and β-
synuclein; α- and γ-synuclein, β- and γ-synuclein, with
subsequent measurement of free NAbs by ELISA (as de-
scribed above) on plates coated with 10 μg/ml of α-
synuclein. For individual samples (the range was decided
after completing preliminary experiments) 1000, 100 and
10 nM concentrations of α-, β-, and γ-synuclein mono-
mers were used in the same combinations as for the in-
hibition curves. To obtain relative maximum of
inhibition, each sample has been preincubated with high
concentration (1000 nM) of mixed together α-, β-, and
γ-synuclein.
Sample analyses
The relative binding of anti-α-, β-, and γ-synuclein NAbs
is expressed as a percentage of maximum binding ob-
served in the assay for each sample; the competition re-
actions with 1000 nM α-, β- or γ-synuclein monomer
were defined as representing 0% binding (unspecific
binding), and reactions without competition are taken to
indicate 100% (maximum) of binding in the displace-
ment curves. For the inhibition assays, results are
expressed as % inhibition calculated as [(OD450 of non-
inhibited sample) ÷ (OD450 of inhibited sample)] × 100/
OD450 of non-inhibited sample, where OD450 is the op-
tical density at 450 nm.
Due to unequal group sizes, non-normal distribution
of some variables, and rank-order ratings on the Hoehn
and Yahr staging scale, non-parametric tests (The Krus-
kal–Wallis one-way analysis of variance, Mann–Whitney
U Test and Spearman correlation) were used for group
comparisons and correlation analyses. All tests were car-
ried out using GraphPad Prism software v.6 (GraphPad
Software Inc., La Jolla, CA). Differences were considered
significant at the P value of less than 0.05.
Analysis of the competition binding curves was per-
formed according to the one- and two-site models using
computer-assisted curve fitting Fit logIC50 model
(GraphPad Software Inc., La Jolla, CA)
Results
Pre-analytical evaluations of competitive ELISA set-ups
Polyclonal plasma antibodies against a particular antigen
potentially comprise a mixture of antibodies with differ-
ent epitope specificities and affinities. We employed the
competitive ELISA method to measure relative binding
properties of the composite of anti-α-synuclein NAbs in
plasma, exploiting the stronger antibody-antigen interac-
tions of high affinity antibodies. By incubating plasma
samples with increasing concentrations of free α-
synuclein monomer prior to measurement of free anti-
body titre on plates with immobilized α-synuclein
monomer we were able to separate anti-α-synuclein
NAbs into a low and high affinity/avidity pools. The sche-
matic diagram of the assay setup is presented in Fig. 1.
For the initial series of experiments, 10 randomly
selected plasma samples from each group were pooled.
The pooled samples were used to determine the appro-
priate plasma dilutions suitable for inhibition assays, as
well as the concentrations of the coating antigen
required to test the individual samples in the later part
of the study. Fig. 2a, b present examples of the binding
curves obtained in competitive ELISA, showing distinct
apparent affinity profiles of anti-α-synuclein plasma
NAbs from PD, MSA patients and normal controls.
These displacement curves are expressed as percentage
of the maximal binding measured in the absence of free
α-synuclein monomers. High affinity/avidity is indicated
by efficient inhibition of antibody binding in the pres-
ence of low (1–10 nM) concentrations of α-synuclein,
whereas low affinity/avidity binding type is revealed by
inhibition at a high concentration (10–1000 nM). The
inhibition curve distinctly follows a two-site model for
plasma from normal controls, indicating that a substan-
tial fraction (approximately 50%) of total antibody bind-
ing is characterized by antibodies with high apparent
affinity/avidity. The remaining part of total antibody
binding indicates antibodies of low affinity, as well as the
contribution of unspecific binding. Displacement curves
from PD patient plasma samples also supported a two-
affinity state model but, with a reduced fraction of high
affinity antibodies. In contrast, the MSA plasma required
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Fig. 1 Schematic overview of the competitive ELISA technique. Before transfer onto plates coated with α-synuclein monomer, plasma samples are
incubated for 1 h at RT with α-synuclein monomer. Following washing steps, the competition reaction is created by moving plasma/α-synuclein
monomer samples onto the coated plate. Here, high affinity antibodies form more stable bonds with free antigen than do lower affinity antibodies.
Consequently, lower affinity antibodies remain bound to the excess immobilized antigen on the plates, but high-affinity antibodies bound to
the fluid-phase antigen are washed away. After several washes, the amounts of low-affinity antibodies remaining on the plates are detected
by peroxidase-labelled polyclonal goat anti-human IgG (Fc fragment specific). The plate is developed by adding an enzymatic substrate to
produce a visible signal
Fig. 2 The two site inhibition curves show distinct high and low binding components in plasma from Parkinson’s Disease (PD-blue, squares),
Multiple System Atrophy (MSA-green, triangles) patients and normal control (NC-black, circles) subjects. Ten plasma samples from each group
were pooled and incubated with increasing concentration of α-synuclein monomer with subsequent measurement of free NAbs by ELISA or
Meso Scale Discovery (MSD) assays. a ELISA: 10 μg/mL α-synuclein coating, plasma dilution 1:400; b ELISA: 5 μg/mL α-synuclein coating, plasma
dilution 1:200; c MSD assay: 5 ng/mL α-synuclein coating, plasma dilution 1:500. The relative binding of anti-α-synuclein NAbs is expressed as
a percentage of maximal binding attained in the assay for each sample, where competition reactions with 1000 nM α-synuclein monomer are
defined as constituting non-specific (background) binding and reactions without competition reflect 100% (maximum) binding. The line
represents the fitting of a two site model to the data
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high α-synuclein concentration for inhibition indicating
an absence of high affinity antibodies. These results were
further supported by using the MSD assay platform. By
applying the MSD assay we were able to reduce the con-
centration of coating antigen from 10 μg/mL and 5 μg/mL
to 5 ng/mL (Fig. 2c) and 0.5 ng/ml (not shown), due to
sensitivity of the assay, and to test the pooled plasma
samples at 1:500 dilutions. The binding curves obtained
by MSD were in accordance with those obtained using
ELISA, in that we could further discern the two site
binding model comprising a high affinity component at
low nM range and a low affinity group with approxi-
mate affinity around 1 μM.
To evaluate the specificity of the binding of anti-α-
synuclein plasma NAbs, control competition assays were
conducted on the pooled plasma samples using antigens
unrelated to synucleinopathies. Here we performed
ELISA assay using either α-synuclein monomer or amyl-
oid β1–40 (Aβ1–40) peptides in the fluid inhibition
phase and plates coated with α-synuclein at 5μg/mL
(Figs. 3a, b). The α-synuclein monomer were able to in-
hibit plasma NAbs binding in all tested groups (Fig. 3a),
whereas there was no inhibition detected with Aβ1–40
(Fig. 3b) suggesting the specificity of anti-α-synuclein
plasma NAbs.
Binding properties of anti-α synuclein NAbs
Consequently, we proceeded with the ELISA set-up to test
the binding properties of the anti-α-synuclein NAbs in the
individual plasma samples from all 46 PD and 18 MSA
patients, and the 41 controls. . Each plasma sample was
diluted 1:100 and 1:200 with PBS and preincubated with
low 2 nM, 50 nM (Fig. 4a–d respectively) and high con-
centrations (1 μM) of free α-synuclein monomer to satur-
ate the inhibition reaction, followed by incubation on
plates coated with 5 μg/ml of immobilized α-synuclein.
The data show that in the presence of 50 nM free
α-synuclein monomer a binding of approximately 70–80%
of the maximal binding is obtained for anti-α-synuclein
NAbs in plasma from MSA patients. The corresponding
values for PD and normal controls are significantly lower
50–55% and 40–45% respectively (Fig. 4a–b), indicating
that these plasma samples contain a significant larger pro-
portion of high affinity anti-α-synuclein NAbs compared
to MSA patients. In the same experiment performed in
the presence of 2 nM free α-synuclein monomer a binding
of approximately 90–95% of the maximal binding is ob-
tained for anti-α-synuclein NAbs in plasma from MSA pa-
tients. The corresponding values for PD and normal
controls are approx. 80% and 70–75% respectively, (Fig.
4c-d). Under these conditions both MSA and PD are sig-
nificant different from healthy controls, meaning that both
MSA and PD patients contains a significant lower amount
of high affinity anti-α-synuclein NAbs in plasma compared
to controls. These are the key findings in the study.
We furthermore tested the ability of α-synuclein mono-
mer to inhibit binding to α-synuclein coated plates of
NAbs from individual samples, using the same conditions
as described for maximal binding in the experiments
above. We expressed the percent inhibition relative to that
in the unblocked plasma, i.e. samples with no free antigen
added. Both 1:100 (Fig. 5a) and 1:200 (Fig. 5b) diluted
plasma samples from MSA patients had significantly
reduced binding capability for α-synuclein monomer in
comparison with plasma samples from PD patients and
healthy controls. Only with a low plasma concentration
(1:200) and high antigen levels (1 μM) could we achieve
comparable inhibition in all groups (Fig. 5b). This further
supports our finding of absence of high affinity anti-α-
synuclein NAbs in plasma samples from MSA patients.
Effect of age
There is evidence suggesting that the general changes in
the humoral immune responses with age are qualitative
Fig. 3 Specificity of anti-alpha-synuclein NAb binding. The ability of increasing concentrations of a α-synuclein monomer or b amyloidβ1–40
(Aβ1–40) to inhibit the binding of α-synuclein NAbs to α-synuclein coated ELISA plates. Data are presented as % inhibition (PI) relative to the
unblocked condition. Pooled plasma samples are from 10 Parkinson’s Disease (PD-blue, squares), 10 Multiple System Atrophy (MSA-green, triangles)
patients and 10 normal controls (NC-black, circles) were diluted 1:400. The lines in a represents the fitting of a one site model to the data
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rather than quantitative, i.e. it is the affinity and specificity
of the antibodies that change, rather than the quantity of
antibodies produced [33]. Due to the difference in mean
age of our control subjects (Table 1), we tested if the max-
imal binding to α-synuclein of NAbs from elderly controls
(>50 years old) differed from that of younger controls
(<50 years old). There was no significant difference in
binding properties of anti-α-synuclein NAbs from plasma
of controls stratified by age, either at a dilution of 1:100
(Fig. 6a, b) or 1:200 (Fig. 6d, c).
Levels of plasma α-synuclein and α-synuclein/NAbs
complexes
In addition to measuring the individual binding proper-
ties of the plasma NAbs, we also measured the concen-
tration of plasma α-synuclein and α-synuclein/NAbs
complexes. The mean (±SD) plasma concentration of
α-synuclein was significantly higher in the control group
(127 ± 8.3 ng/ml) than for PD (100.2 ± 3.2 ng/ml;
p = 0.015) and MSA (98.6 ± 3.1 ng/ml; p = 0.024)
patients (Fig. 7a). To measure α-synuclein/NAbs com-
plexes in plasma, the α-synuclein detection antibody in
the human α-synuclein MSD kit had been substituted
with an equivalent amount of an anti-human IgG anti-
body, while the nature of the capture antibody was
unchanged. The results here show a significantly higher
α-synuclein/NAbs complex concentration in controls
(423 ± 31.2 pg/ml) than in PD (350 ± 21.6 pg/ml;
p = 0.042) and MSA (217 ± 34.7 pg/ml; p = 0.0001)
patients (Fig. 7b). The plasma α-synuclein/NAbs com-
plex concentration was significantly lower in MSA than
PD patients (p = 0.002).
Binding properties of anti-β-synuclein and anti-γ-
synuclein NAbs
The synuclein family consists of α-, β-, and γ-synucleins,
that are 55–62% identical in sequence with most of the
similarity lying within the N-terminus of the proteins
(aa 1–100) and with more variability in sequence
located toward the C-terminus. Because NAbs are often
polyreactive, and may exhibit cross-reactivity, we tested
if the binding properties of the anti-α-synuclein NAbs
would be reflected in anti-β and -γ-synuclein NAbs.
Figures. 8a and 9a present examples of the binding
curves obtained in competitive ELISA on pooled
Fig. 4 Reduced levels of high affinity anti-α-synuclein NAbs in plasma from MSA and PD patients. Binding of anti-α-synuclein NAbs in plasma to
immobilized α-synuclein monomer (5 μg/mL) in competitive ELISA assay in the presence of a, b 50 nM or c, d 2 nM free α-synuclein. Non-specific
binding is defined as the binding to the plate in the presence of 1000 nM free α-synuclein monomer. Maximal binding is defined as the binding
observed in the absence of added free α-synuclein monomer. Horizontal bars represent the mean values +/− SEM. Plasma samples from Parkinson’s
Disease (PD), Multiple System Atrophy (MSA) patients and normal controls (NC) were tested at two dilutions, i.e. a, c 1:100 and b, d 1:200. Significance
was tested using Man–Whitney’s U test (P < 0.05)
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samples (n = 10) for each disease and controls, showing
similar apparent affinity profiles of anti-β-synuclein and
anti-γ-synuclein, respectively, for plasma NAbs from
PD, MSA patients and normal controls. Further, we
proceeded with the ELISA set-up to test the binding
properties of the anti-β and anti-γ-synuclein NAbs in
the individual plasma samples from all 46 PD and 18
MSA patients, and the 41 controls. Each plasma sample
was diluted 1:400 with PBS and preincubated with low
(10 nM and 100 nM) and high concentrations (1 μM)
of either free β-synuclein (Fig. 8b, c) or γ-synuclein
monomer (Fig. 9b, c), followed by incubation on plates
coated with 10 μg/ml of immobilized β- or γ-synuclein
respectively. The data show that in the presence of
10 nM free β- or γ-synuclein monomer a binding of
approximately 50–70% of the maximal binding is
obtained for anti-β- and anti-γ-synuclein NAbs in
plasma from all three groups. The corresponding values
for 100 nM free β- or γ-synuclein monomer are also
similar in all tested groups and are in the range of 40–45%.
These data suggest that there are no differences in the
levels of high and low affinity components of anti-β- and
anti-γ-synuclein NABs in plasma from PD, MSA patients
and normal controls.
Cross-binding experiments
To evaluate cross-reactivity of anti-α-synuclein high and
low affinity plasma NAbs with β- and γ-synuclein mono-
mers, we have performed cross-binding ELISA set-ups.
The inhibition curves for the scenario where α-synuclein
is present simultaneously with either β- or γ synuclein
distinctly follows a two-site model seen before with free
α-synuclein (Fig. 10a and b). Accordant to the α-synuclein
experiments plasma from normal controls, is character-
ized by antibodies with high apparent affinity/avidity. PD
plasma samples also supported a two-affinity state model,
but with a reduced fraction of high affinity antibodies, and
to a lesser extent in comparison to when α-synuclein was
present alone. MSA plasma samples required high α−/β-
synuclein and α−/γ-synuclein concentrations for inhib-
ition indicating an absence of high affinity antibodies. In
the simultaneous presence of increasing concentrations of
free β- and γ-synuclein monomers prior to measurement
of free antibody titre on plates coated with α-synuclein
monomer (Fig. 10c) plasma samples from normal individ-
uals still supported a two-affinity state model but to a
lower extend than in the previous set-ups, whereas plasma
samples from PD and MSA patients required high β−/γ-
synuclein concentrations for maximum of inhibition.
These data indicate that anti-α-synuclein NAbs from
normal controls cross-react with β- and γ-synuclein
monomers whereas such cross-binding is not found in
PD and MSA patients.
Subsequently, each individual plasma sample was
diluted 1:400 with PBS and preincubated with low
(10 nM or 100 nM) and high concentrations (1 μM) of
free α-, β-, and γ-synuclein monomers in combinations
analogous to the inhibition curve experiments, followed
by incubation on plates coated with 10 μg/ml of immo-
bilized α-synuclein. The data are presented as percent of
inhibition relative to 100% where high levels (1 μM) of
each α-, β-, and γ-synuclein were added simultaneously to
the reaction, and to the unblocked plasma, i.e. samples with
no free antigen added. The data show that in the presence
of 100 nM free proteins an inhibition of approximately
60–70% is obtained for combinations α−/β-synuclein and
Fig. 5 Plasma samples from MSA patients have significantly reduced
binding capability to α-synuclein monomer. Average percentage
(± − SEM) of inhibition (PI) of individual plasma samples with free
α-synuclein monomer on plates coated with 5 μg/mL of α-synuclein
monomer. Plasma samples from Parkinson’s Disease (PD-blue squares),
Multiple System Atrophy (MSA-green, triangles) patients and normal
controls (NC-black, circles) were tested at two different dilutions a
1:100 and b 1:200. The line represents the fitting of a two-site
model to the data (*p < 0.05)
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α−/γ synuclein in plasma from normal controls. The
corresponding values for PD and MSA patients are sig-
nificantly lower 50% and 30% respectively for α−/β-sy-
nuclein (Fig. 10d), and 60% and 30% respectively for
α−/γ synuclein. Notably in the presence of α−/γ synuclein
we did not observe significant differences between healthy
individuals and PD patients. In the presence of 10 nM
concentrations of free α−/β-synuclein (Fig. 10e) and α−/γ
synuclein (Fig. 10g) significant differences in the percent-
age of inhibition were observed in plasma from controls
and PD patients vs. MSA patients, whereas no difference
was found between PD patients and control individuals.
The inhibition levels of anti-α-synuclein NAbs by simul-
taneous presence of 100 nM β- and γ-synuclein mono-
mers were decreased in comparison to the previous
approach in normal controls and PD patients (approxi-
mately 40–45%), but still significantly higher than in MSA
patients (Fig. 10h). No differences between the groups
were observed with 10 nM of free β- and γ-synuclein
monomers (Fig. 10i).
Fig. 6 Absent correlation of age and binding properties of anti-α-synuclein NAbs in plasma from negative controls. Percentage of maximal plasma
NAbs binding to immobilized α-synuclein monomer (5 μg/mL) in younger controls (<50 years old, n = 26) and in elderly controls (>50 years old,
n = 15) determined by competitive ELISA assay with a, b 50 nM or c, d 2 nM of free α-synuclein, where 10,000 nM defines the non-specific binding
and no free α-synuclein monomer gives the maximal binding. Horizontal bars represent the mean values ± SEM. Plasma samples were diluted tested
in two different dilutions: a, c 1:100 and b, d 1:200
Fig. 7 Concentrations of α-synuclein a and α-synuclein-NAbs complexes b in plasma from Parkinson’s Disease (PD), Multiple System Atrophy (MSA) pa-
tients and normal controls (NC). Horizontal bars represent the mean values ±SEM. α-Synuclein-NAbs complex concentrations were quantified using α-
synuclein standard curve. Significance was tested using Man–Whitney’s U test (P < 0.05)
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These data suggest the high affinity anti-α-synuclein
plasma components, seen in healthy individuals, are
selective for physiologically relevant epitopes and prob-
ably react solely with C-terminal epitopes of α-synuclein.
Binding properties of anti-P-α-synuclein NAbs
Posttranslational modifications of α-synuclein, particularly
phosphorylation at serine 129, may be critical in patho-
genesis of PD and MSA [34]. The neuropathological diag-
nosis of PD and MSA is often based on specific regional
distribution of P-α-synuclein in glial cells and neurons of
the CNS, respectively. Therefore, we tested if the binding
properties of the anti-α-synuclein NAbs would also be
reflected in anti-P-α-synuclein NAbs. For that, an α-synu-
clein monomer preparation was phosphorylated with a
serine⁄threonine kinase PLK2. PLK2 is a principle con-
tributor to α-synuclein phosphorylation at Ser-129 in
neurons and directly phosphorylates α-synuclein at
Ser-129 in in vitro biochemical assays [35].
To test binding properties of the anti-P-α-synuclein
NAbs, each plasma sample was diluted 1:400 with PBS
and preincubated with low 1 nM, 0.1 nM (Fig. 11a–d,
respectively) and high concentrations (10 nM) of free
P-α-synuclein to saturate the inhibition reaction, followed
by incubation on plates coated with 10 ng/ml of immobi-
lized either α-synuclein (11a, b) or P-α-synuclein (11c, d).
The data show that in the presence of 1 nM free P-α-
synuclein monomer binding to plates coated with either
α-synuclein (Fig. 11a) or P-α-synuclein (Fig. 11c) of
approximately 35%–45% and 50–60% of the maximal
binding is obtained for anti-P-α-synuclein NAbs in
plasma from PD and MSA patients respectively. The
corresponding values for normal controls are significantly
lower, 15–20%, indicating that these plasma samples con-
tain a significant larger proportion of high affinity anti-P
Fig. 8 β-synuclein competition ELISA assays. a The two site inhibition curves show high and low binding components in pooled plasma samples
from Parkinson’s Disease (PD-blue, squares), Multiple System Atrophy (MSA-green, triangles) patients and normal control (NC-black, circles) subjects.
10 μg/mL β-synuclein coating, plasma dilution 1:400; b and c: Binding of anti-β-synuclein NAbs in individual plasma samples to immobilized β-synuclein
monomer (10 μg/mL) in competitive ELISA assay in the presence of b 100 nM or c 10 nM free β-synuclein. Non-specific binding is defined as the binding
to the plate in the presence of 1000 nM free β-synuclein monomer. Maximal binding is defined as the binding observed in the absence of added free
β-synuclein monomer. Plasma samples were tested at 1:400 dilution. Horizontal bars represent the mean values +/− SEM. Significance was tested using
Man–Whitney’s U test (P < 0.05)
Fig. 9 γ-synuclein competition ELISA assays. a The two site inhibition curves show high and low binding components in pooled plasma samples
from Parkinson’s Disease (PD-blue, squares), Multiple System Atrophy (MSA-green, triangles) patients and normal control (NC-black, circles) subjects.
10 μg/mL γ-synuclein coating, plasma dilution 1:400; b and c: Binding of anti-γ-synuclein NAbs in individual plasma samples to immobilized γ-synuclein
monomer (10 μg/mL) in competitive ELISA assay in the presence of b 100 nM or c 10 nM free γ-synuclein. Non-specific binding is defined as
the binding to the plate in the presence of 1000 nM free γ-synuclein monomer. Maximal binding is defined as the binding observed in the
absence of added free γ-synuclein monomer. Plasma samples were tested at 1:400 dilution. Horizontal bars represent the mean values +/− SEM.
Significance was tested using Man–Whitney’s U test (P < 0.05)
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α-synuclein NAbs compared to MSA patients. In the same
experiment performed in the presence of 0.1 nM free P-α-
synuclein a binding of approximately 80–90% and 70–80%
of the maximal binding is obtained for anti-P-α-synuclein
NAbs in plasma from PD and MSA patients, respectively.
The corresponding values for normal controls are
40–50%% on plates coated with either α-synuclein
(Fig. 11b) or P-α-synuclein (Fig. 11d). Under these condi-
tions both MSA and PD are significantly different from
healthy controls, meaning that plasma samples from
MSA and PD patients contain a significantly lower
amount of high affinity anti-P-α-synuclein NAbs com-
pared to normal controls.
Discussion
Previously, it has been hypothesized that the anti-α-
synuclein NAbs levels may be a factor contributing to
the pathogenesis of PD [23–29]. However, there was no
consistent finding for a change in the anti-α-synuclein
NAbs concentration in plasma from PD patients relative to
healthy individuals. No study has investigated the avidity of
the anti-α-synuclein NAbs in PD and MSA patients, which
is possibly more relevant than mere concentrations.
This is the first report on anti-α-synuclein NAbs in
MSA, and the first report to link the affinity/avidity of nat-
urally occurring anti-α-synuclein autoantibodies to the
clinical phenotypes of PD and MSA. Using a conventional
Fig. 10 Cross-binding competition ELISA assays. a, b, and c: The two site inhibition curves show distinct high and low binding components in
plasma from Parkinson’s Disease (PD-blue, squares), Multiple System Atrophy (MSA-green, triangles) patients and normal control (NC-black, circles)
subjects. Ten plasma samples from each group were pooled and incubated in 1:400 dilution with increasing concentration of α-, β-, and γ-synuclein
monomers in combinations as indicated, with subsequent measurement of free NAbs by ELISA on plates coated with 10 μg/ml of α-synuclein.
d-i: Percentage of inhibition (PI) of individual plasma samples with free d, e: α−/β-synuclein monomers, F, G: α−/γ-synuclein monomers; h, i:
β−/γ-synuclein monomer on plates coated with 10 μg/mL of α-synuclein monomer. Plasma samples from Parkinson’s Disease (PD), Multiple
System Atrophy (MSA) patients and normal controls (NC) were tested at 1:400 dilution in the presence of (d, f, h) 100 nM or (e, g, i) 10 nM
α-, β-, and γ-synuclein monomers in combinations. Horizontal bars represent the mean values +/− SEM. Significance was tested using
Man–Whitney’s U test (P < 0.05)
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immunoassay set-up, we assessed the NAbs apparent
affinity/avidity by fitting one- and two site models to the
inhibition curves obtained by adding increasing amounts
of α-synuclein monomer to diluted plasma samples. We
report that a two-site model proved superior, indicating
approximately equal low and high binding components in
healthy controls, but a lower fraction of high affinity anti-
α-synuclein NAbs in PD patients, and a near absence of
the high affinity component in plasma from MSA patients.
As with the present results, the antibody affinity and avid-
ity distribution did not vary with age, substantiating our
claim that age is not a factor in the present α-synuclein
NAb findings. Moreover, we did not find a correlation
between disease duration or disease severity and the NAb
affinity distribution in PD or MSA nor any differences
between males and females (data not shown). This may
suggest that the NAbs are not a predictor of disease pro-
gression in these diseases, but it does not rule in or out
the contribution of NAbs to the control of PD and MSA
progression and maybe also as a prognostic tool.
Serine 129 phosphorylated α-synuclein is a major
component of neuronal Lewy bodies in PD and of glial
cytoplasmatic inclusions in MSA [34]. Phosphorylated
α-synuclein can be detected in blood plasma and shows
more promise as a diagnostic marker than the nonpho-
sphorylated protein as the levels of P-α-synuclein are
higher in PD than in controls [36–38]. We showed near
absence of the high affinity anti-P-α-synuclein compo-
nent in plasma from PD and MSA patients.
The progressive pathological changes in PD and MSA
probably start years before the clinical onset of motor-
symptoms. The discovery of α-synuclein aggregates in
nerve endings of the heart [39], digestive tract (reviewed
by Ruffman and Parkkinen [40]), and skin [41, 42] has
lent support to the concept of PD as a systemic disease.
Braak and coworkers hypothesized that Lewy Body path-
ology primes in the enteric nervous system and spreads to
the brain, suggesting an active retrograde transport of
α-synuclein via vagal nerve [43]. Moreover, P-α-synuclein
has been detected in the gastrointestinal tract of PD
patients and healthy controls [44–47] suggesting that that
α-synuclein phosphorylation is a physiologically occurring
process. These observations suggest that the immune
system is exposed to misfolded, phosphorylated and
aggregated forms of α-synuclein already in the early
stage in the course of the disease and thus impaired
antibody-mediated clearance mechanisms may lead to
the progression of the pathology in synucleinopathies.
Fig. 11 Reduced levels of high affinity anti-phosphorylated (P) α-synuclein NAbs in plasma from MSA and PD patients. Binding of anti-P-α-synuclein
NAbs in plasma to immobilized a, b α-synuclein monomer (10 ng/mL) or c, d P-α-synuclein (10 ng/mL) in competitive MSD assay in the presence of
a, c 1 nM or b, d 0.1 nM free P-α-synuclein. Non-specific binding is defined as the binding to the plate in the presence of 100 nM free P-α-synuclein
monomer. Maximal binding is defined as the binding observed in the absence of added free α-synuclein monomer. Horizontal bars represent the
mean values +/− SEM. Plasma samples from Parkinson’s Disease (PD), Multiple System Atrophy (MSA) patients and normal controls (NC) were tested
at 1:400. Significance was tested using Man–Whitney’s U test (P < 0.05)
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T- and B-lymphocyte subsets are declined in a PD
patient cohort during a 5 and 10 year disease course
[48] probably contributing to the changes in variability
of anti-α-synuclein antibody responses.
NAbs are crucial for microglial phagocytosis of
antibody-antigen complexes [49], dissociating aggregates
and inhibiting pathological protein aggregation [50] by
stabilizing a specific type of an aggregate [51] or by
binding an epitope only accessible in a specific protein
conformation [52, 53]. Recent observations by Breydo et
al. have shown that antibodies can interfere with protein
aggregation at substoichiometric concentrations [54].
Interestingly, Inhibition was especially effective in the
absence of seeds indicating that early stages in the aggre-
gation pathway were the major targets of the antibody
binding.
At this point we may only speculate that high affine
α-synuclein antibodies can neutralize the neurotoxic
aggregates without interfering with beneficial functions
of monomeric α-synuclein. In fact, single chain antibody
fragments (scFvs) were isolated from a phage displayed
antibody library against the target antigen morphology.
These scFvs were proved to bind only to an oligomeric
form of α-synuclein and inhibit both aggregation and
toxicity of α-synuclein in vitro [55]. Recently, it has also
been shown that the robust uptake of α-synuclein oligo-
mer/protofibril selective antibodies by human Central
Nervous System (CNS)-derived cells is enhanced by
extracellular α-synuclein and mediated via Fcγ receptors
[56]. Other monoclonal antibodies have been suggested
to promote phagocytosis and lysosomal degradation of
α-synuclein [57].
Our finding of decreased plasma α-synuclein concen-
trations both in PD and MSA groups stands in contrast
to previous studies based on traditional sandwich ELISA,
which reported increased plasma α-synuclein in these
patient groups [36, 58]. The discrepancy may reflect sev-
eral factors such as sample characteristics, biological
sample quality, and especially the nature of the detection
antibodies. For example, the different primary antibodies
may detect to a varying degree truncated α-synuclein, as
well as full-length protein or oligomers forms. Consistent
with our results, studies using Western blotting
reported decreased plasma α-synuclein levels in PD
patients [36, 59]. We speculate that decreased plasma
levels of α-synuclein in MSA and PD may reflect the
increased α-synuclein load in the brain of this normally
cytoplasmic protein [60]. The finding of decreased
plasma α-synuclein is further supported by the reduced
levels of anti-α-synuclein/NAbs complexes in plasma
from PD patients, which was even more pronounced in
the MSA group. We can only speculate that the oligo-
mers are transiently present also in healthy individuals,
but are adequately cleared by a natural autoimmune
mechanism, which is facilitated by the affine binding of
NAbs to α-synuclein. PD and MSA occurs mainly in
elderly and aging greatly increases the risk of a slow
but progressive protein aggregation, thus it can be one
of the factors in individuals at risk, which puts a greater
stress on the clearance system [28].
The synuclein family consists of three distinct pro-
teins, α-synuclein, β-synuclein, and γ-synuclein sharing
many common epitopes [61]. All synuclein protein
sequences consist of a highly conserved amino-terminal
domain that includes a variable number of 11-residue
repeats and a less-conserved carboxy-terminal domain that
includes a preponderance of acidic residues. The only sig-
nificant variations within the repeat domain are the dele-
tion of 11 amino acids (residues 53–63) in β-synuclein.
γ-synuclein is smaller than α- and β-synucleins due to a
shorter C-terminal region, yet it contains much of the non-
Abeta component (NAC) that is missing in β-synuclein
[62, 63]. The amino-terminal half of all synucleins is
taken up by a highly conserved alpha-helical lipid-
binding motif. β-synuclein contains five of these domains,
whereas α- and γ-synucleins have six. Despite similar
repeat sequences, β-synuclein and γ-synuclein show poor
assembly into filaments [61, 64] and have no pathologic-
ally disease relation in PD and MSA. In fact, in vitro stud-
ies have also shown that both β- and γ-synuclein are able
to inhibit fibrillation of α-synuclein [65, 66]. The C-ter-
minal regions of synucleins, although all highly acidic, are
rather different. It is probably this structural diversity that
leads to differences in NAbs reactivity towards synucleins.
Our observations may suggest, the high affinity anti-α-
synuclein plasma component, seen in healthy individuals,
is directed mainly against C-terminal epitopes or binds to
an oligomeric form of α-synuclein. Here, by applying in-
hibitory ELISA, which detects proteins in a solution, anti-
α-synuclein NAbs were shown to be truly selective for
physiologically relevant epitopes that are accessible for the
antibodies. This may reflect the situation in vivo in healthy
individuals, where the high affinity component of anti-α,
−β and -γ-synuclein plasma NAbs reacts with mutual epi-
topes present on α-synuclein.
Conclusions
The relatively mild, but significant, decrease in high
affinity anti-α-synuclein NAbs in plasma of PD patients
may parallel the slow progression of PD pathology,
whereas the rapidly progressing pathology characteristic
of MSA could be attributed to the near absence of high
affinity anti-α-synuclein NAbs. This implies that im-
paired capacity for immune clearance and/or blocking of
toxic α-synuclein species may be a factor in these dis-
eases, and support the rationale for immunotherapy with
high affine α-synuclein antibodies as a new disease alter-
ing approach to treatment [67]. The disease-associated
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anti α-synuclein NAb alterations in individual autoanti-
body profiles may also present a new approach for early
diagnosis of these neurodegenerative diseases. To what
extent the same anti α-synuclein NAb profile is present
in cerebrospinal fluid (CSF) and by what mechanisms
these autoantibodies seems to play a role in slowing dis-
ease development remains to be elucidated.
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